A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis

Nature

Volumn 520, Issue 7547, 2015, Pages 358-362

  Wagenblast, Elvin ^a   Soto, Mar ^a   Gutiérrez Ángel, Sara ^a   Hartl, Christina A ^a   Gable, Annika L ^a   Maceli, Ashley R ^a   Erard, Nicolas ^a,b   Williams, Alissa M ^a   Kim, Sun Y ^a   Dickopf, Steffen ^a   Harrell, J Chuck ^c   Smith, Andrew D ^d   Perou, Charles M ^c   Wilkinson, John E ^e   Hannon, Gregory J ^a,b   Knott, Simon R V ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CD31 ANTIGEN; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERPINE 2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; PROTEASE NEXIN I; SERPINE2 PROTEIN, MOUSE; SLPI PROTEIN, MOUSE;

CANCER; GENE EXPRESSION; HETEROGENEITY; MIMICRY; PHENOTYPE; PROTEIN; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER MODEL; CANCER SIZE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; LYMPHATIC SYSTEM; METASTASIS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA SEQUENCE; TROPISM; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR MIMICRY; ANIMAL; BREAST TUMOR; CELL CLONE; DISEASE COURSE; DISEASE MODEL; DNA SEQUENCE; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; RECURRENT DISEASE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTICOAGULANTS; BREAST NEOPLASMS; CLONE CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; RECURRENCE; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SEQUENCE ANALYSIS, DNA; SERPIN E2;

EID: 84928391898     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14403     Document Type: Article

References (26)

1. Vanharanta, S. & Massague, J. Origins of metastatic traits. Cancer Cell 24, 410-421 (2013).
2. Miller, F. R., Miller, B. E. & Heppner, G. H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3, 22-31 (1983).
3. Miller, B. E., Miller, F. R., Wilburn, D. & Heppner, G. H. Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res. 48, 5747-5753 (1988).
4. Fidler, I. J. & Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893-895 (1977).
5. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38, 2651-2660 (1978).
6. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
7. Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014).
8. Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008).
9. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
10. Braun, S. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342, 525-533 (2000).
11. Harrell, J.C. et al. Genomicanalysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res. Treat. 132, 523-535 (2012).
12. Amiano, N. O. et al. Anti-tumor effect of SLPI on mammary but not colon tumor growth. J. Cell. Physiol. 228, 469-475 (2013).
13. Fayard, B. et al. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 69, 5690-5698 (2009).
14. Martin, K. J., Patrick, D. R., Bissell, M. J. & Fournier, M. V. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE 3, e2994 (2008).
15. Rosso, M. et al. Secretory Leukocyte Protease Inhibitor (SLPI) expression downregulates E-cadherin, induces beta-catenin re-localisation and triggers apoptosis-related events in breast cancer cells. Biol. Cell 106, 308-322 (2014).
16. Sayers, K. T., Brooks, A. D., Sayers, T. J. & Chertov, O. Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells. PLoS ONE 9, e104223 (2014).
17. Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002-1016 (2014).
18. Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752 (1999).
19. Hendrix, M. J., Seftor, E. A., Hess, A. R. & Seftor, R. E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev. Cancer 3, 411-421 (2003).
20. Folberg, R., Hendrix, M. J. & Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361-381 (2000).
21. Ruf, W. et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res. 63, 5381-5389 (2003).
22. Cao, Z. et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur.J. Cancer 49, 3914-3923 (2013).
23. Langmead,B., Trapnell, C., Pop,M.&Salzberg, S. L. Ultrafast andmemory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
24. Langmead, B.&Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nature Methods 9, 357-359 (2012).
25. Anders, S., Pyl, P. T.&Huber, W.HT Seq-A Python framework towork with highthroughput sequencing data. Bioinformatics 31, 166-169 (2015).
26. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).